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Sir—We read with interest the article by
Sendi et al. [1] on the safety of intranasal
and injectable influenza vaccines in a
working Swiss population. They report
that, of the 13% of the subjects who
wished to be vaccinated, the nasal route
was the preferred route of administration
for 97%. This is a striking finding, and we
would like to know what information was
provided to the volunteers for them to
make their choices. Indeed, at that time
(winter 2000), to our knowledge, there
were no published safety data with side-
by-side comparisons of the 2 types of vac-
cines; more importantly, there were no data
on immunogenicity (protective antibody
titers) and, therefore, on the efficacy for
humans of the specific intranasal vaccine
used (Nasalflu; Berna Biotech AG). Thus,
we wonder on what grounds the subjects
mentioned “increased efficacy” as a reason
for choosing the nasal spray (23% in table
1 of [1]). Was that information suggested
by the information leaflet?
We made an acceptability assessment
during the winter season of 1999–2000 in
an elderly population attending the Med-
ical Outpatient Clinic, University of Lau-
sanne (Lausanne, Switzerland) as part of
a comparative safety and immunogenicity
trial. Our findings are very different from
those of Sendi et al. [1]. Indeed, only 98
(25%) of 400 elderly persons agreed to be
randomized—in other words, to poten-
tially receive the intranasal vaccine (Na-
salflu; Berna Biotech AG). The main rea-
sons they gave to potentially receive the
mucosal route were “to try” it and because
they “don’t like injections.” The other
75% of persons preferred to receive the
conventional injectable vaccine, with the
main reasons being “one shot and that’s
done,” “I am used to it,” and “I have prob-
lems with my nose.” Because the subjects
were recruited upon usual attendance for
flu vaccination, and because the study pro-
tocol did not include many constraints
(only 1 additional visit and 2 blood draws
were required), it is unlikely that partici-
pation in the trial was the main reason for
the low acceptance of the intranasal vac-
cine. Moreover, during the subsequent
winter season, we let the working personal
of the Medical Outpatient Clinic freely
choose between the intranasal or the in-
tramuscular vaccine. Among those who
accepted vaccination, 19% chose the in-
tranasal route, and 81% chose the intra-
muscular route, which is very far from the
rates of 97% and 3%, respectively, among
the employees of the Canton Basel Stadt
reported by Sendi et al. [1].
The study by Sendi et al. [1] was aimed
primarily at assessing the safety of a new
intranasal vaccine. It definitely contrib-
uted to the identification of an important
severe adverse event (i.e., facial palsy), a
finding that was supported by a later study
[2]. However, the design was not appro-
priate to assess subjects’ preference for one
vaccine or the other, and this may explain
the very different findings between 2
young working communities within the
same country. Thus, we doubt the authors’
conclusions on public preference based on
these data. Such variability calls for well-
designed studies aimed at specifically as-
sessing vaccine route preference among
the public, using standardized informa-
tion based on published peer-reviewed
evidence.
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Reply
Sir—We thank Genton and D’Acremont
[1] for their interest in our article. We
agree with the authors that no data from
a randomized controlled trial comparing
the efficacy of the intranasal versus in-
jectable vaccine are available. However,
immunogenicity and safety data regarding
the virosome-formulated subunit vaccine
containing the heat-labile toxin of Esche-
richia coli were published before winter
2000 [2]. In addition, immunogenicity
and safety data were available from Berna
Biotech AG. It has been argued that the
intranasal vaccine would induce secretory
IgA antibodies (in addition to IgG anti-
bodies) in the nasopharyngeal cavity,
which are able to neutralize influenza vi-
ruses [3]. This may suggest a potentially
higher efficacy [3], although a head-to-
head randomized controlled trial of the
injectable versus intranasal vaccine would
be needed to verify this. In our study, pa-
tients who chose the intranasal vaccine
were less likely to develop influenza-like
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symptoms [4]. However, this difference
was not statistically significant because of
a lack of power, because the number of
patients who received the injectable vac-
cine was very low. In addition, the study
was not designed to detect differences in
effectiveness [4].
In our study, the intranasal vaccine was
the preferred route of administration,
which is quite different from the findings
of Genton and D’Acremont [1]. One rea-
son might be that our study population
was rather young, whereas Genton and
D’Acremont [1] and others [2, 3] included
elderly patients in their studies. Unlike
young healthy adults, elderly individuals
are more susceptible to serious illness after
influenza infection and may therefore
rather benefit from influenza vaccination
[4]. Elderly individuals may also be less
open to novel techniques and might prefer
the vaccine that they are used to—that is,
the injectable vaccine. In a separate article
[5], we analyzed the attitude of the vac-
cinees towards revaccination in the fol-
lowing winter (2001), given their experi-
ence with the influenza vaccine in winter
2000. Our results showed that the decision
to get vaccinated against influenza in the
winter of 2001 did not depend on the
mode of administration (i.e., injectable
versus intranasal vaccine) but, rather, on
the safety and efficacy of the vaccine ex-
perienced by the individuals in the pre-
ceding year. This finding is more in line
with the findings reported by Genton and
D’Acremont [1]. Elderly individuals in
whom influenza vaccination is recom-
mended may have had positive experi-
ences with the vaccine in the past and may
therefore prefer to be revaccinated using
the injectable vaccine that they are used
to. Young healthy adults usually know that
they are able to better cope with influenza
infection than are elderly individuals. They
are also less likely to have been vaccinated
against influenza in the past. The mode of
vaccine administration may therefore be a
more important factor for the young pop-
ulation in deciding whether they wish to
be vaccinated against influenza for the first
time. Finally, we believe that the prefer-
ences of the employees of an outpatient
clinic, who are mostly health care profes-
sionals, may not necessarily coincide with
the preferences of the wider working
population.
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Bactericidal Activity in the
Treatment of Gram-Positive
Bacterial Infections
In their recent review article, Pankey and
Sabath [1] highlight the arbitrariness of
the empirical measures used to define bac-
tericidal and bacteriostatic activities and
emphasize the importance of multiple fac-
tors, such as target organism, organism
burden, site of infection, and intrinsic
pharmacodynamic and pharmacokinetic
properties of individual antimicrobial
agents, as potential determinants of the
efficacy of specific antimicrobial agents
in different clinical circumstances. Their
conclusion, that the potential superiority
of bactericidal over bacteriostatic activity
is of little clinical relevance, however, is
built on a specious line of reasoning. The
arguments Pankey and Sabath [1] pre-
sented simply emphasize both the inap-
propriate pharmacodynamic designation
of antimicrobial agents as either “bac-
tericidal” or “bacteriostatic” solely on the
basis of their mechanism of action and the
notable paucity of clinically validated mea-
sures that discriminate bactericidal from
bacteriostatic activity [2].
Studies by Scheld and Sande [2] using
a rabbit model of pneumococcal menin-
gitis have illustrated the inappropriateness
of designating antimicrobials as “bacteri-
cidal” or “bacteriostatic” solely on the ba-
sis of their mechanism of action. These
studies demonstrated that chloramphen-
icol, an antibiotic generally regarded as
bacteriostatic, can in fact achieve bac-
tericidal activity against Streptococcus
pneumoniae and can achieve microbio-
logic cure rates comparable to that of am-
picillin in the rabbit model of meningitis
when mean peak CSF concentrations ex-
ceeded the minimum bactericidal concen-
tration for the organism. This study, as
well as several others using experimental
animal models, also clearly documented
the need for bactericidal activity to achieve
microbiologic cure of meningitis [3, 4, 5].
Admittedly, little to no suitable clinical
data exist to address the potential supe-
riority or inferiority of bactericidal versus
bacteriostatic activity. Thus, the treatment
offered by Pankey and Sabath should mo-
tivate a renewed interest in reevaluating
this important clinical question. Because
of the unavailability of germane data,
judgment regarding this issue should be
withheld.
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